Clinical Trial Update: Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for RV001V in biochemical failure after curative therapy for localized prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• RV001V (RhoC anticancer vaccine)

Snippet

Sponsor: RhoVac APS | Conditions: Prostate Cancer Recurrent | Phase 2 | Status: ACTIVE_NOT_RECRUITING